Media Archives

• 2007

  Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status from the US FDA and Orphan Medicinal Product Designation from the European Medicines Agency for the Treatment of Tuberculosis (pdf)

  Sequella and Chembio Receive Marketing Approval for New Rapid Detection Diagnostic of Tuberculosis (TB) in Non-Human Primates (pdf)

  Sequella Lead Drug SQ109 Completes Phase 1A Trial (pdf)

  Sequella to Present to Investors During BIO International Convention and Business Forum (pdf)

  Sequella Drug Candidate SQ109 Named as One of 100 Great Investigational Drugs in R&D Directions Article (pdf)

  Dr. Carol Nacy Receives Clinical Trials Award at Women in Bio’s 5th Annual Entrepreneur Dinner (pdf)

  Sequella to present at BIO-Europe Spring 2007 (pdf)

  Sequella Receives U.S. Patent for Translocase Inhibitor Drug Compounds (pdf)

  Sequella Receives FDA Fast Track Status for TB Drug (pdf)

  Dr. Nacy, Sequella CEO, to be featured speaker at Women in Bio 2007 executive forum (pdf)

• 2006

  Science Stops for No Holiday (Washington Post)

  Sequella executive 'focused' on cures (Washington Times)

  Sequella Signs Partnership with Path for TB Patch Clinical Evaluation (pdf)

  Sequella Hires Chief Medical Officer (pdf)

  Sequella Initiates Phase I Clinical Trial for SQ109 (pdf)

  TB in the Headlines: Dangerous new TB strains arriving in U.S. (MSNBC)

  Sequella Releases Clinical Dose-Finding Study Results for TB Patch Diagnostic (pdf)

  Sequella to Present at 2006 ICAAC Conference (pdf)

  Drug-resistant TB on the rise in U.S. (MSNBC)

  Sequella Presents at Merriman Curhan Ford and Company Investor Summit (pdf)

  Dr. Nacy to Receive Leadership Award (pdf)

  Sequella Lead Drug Candidate SQ109 to Begin Clinical Testing in Phase 1 Trial (pdf)

  Sequella Receives Phase 1 SBIR Grant for Translocase I Inhibitors (pdf)

  Sequella Announces Publication of New Diamine Compounds (pdf)

  Sequella and NIH Sign World-Wide Licensing Agreement (pdf)

  Sequella Receives U.S. Patent for Transdermal Patch Diagnostic (pdf)

  Sequella Hires Director of Finance (pdf)

• 2005

  Sequella Presentation at the 45th ICAAC Meeting, Washington, DC (pdf)

  Sequella Receives U.S. Patent for Novel Therapeutic Compounds (pdf)

  Sequella Presentation at the 36th IUATLD World Conference on Lung Health (pdf)

  Sequella Tackles TB Epidemic, The Business Gazette (pdf)

  Sequella Announces Data Presentation at the 2005 Gordon Research Conference on TB Drug Development (pdf)

• 2004

  Sequella, Inc., and Sankyo Co., Ltd. Sign Worldwide Licensing Agreement to Develop and Market Promising New Anti-Tuberculosis Compounds (pdf)

• 2002

  Dr. Carol Nacy of Sequella, Inc. Named As One of Fast Company Magazine's Fast 50 Champions of Innovation (pdf)

• 2002

  Sequella, Inc. Announces Positive Late Stage Clinical Trial Results for a Revolutionary TB Diagnostic (pdf)

• 2001

  Springboard: New England 2001 Selects Sequella, Inc. to Present at November Venture Forum for Women Entrepreneurs (pdf)

  Sequella, Inc. Receives NCI/NIAID Inter-Institute Program Scientific Support for the Development of Novel Second-Generation Drugs for Tuberculosis (pdf)

  Sequella, Inc. Receives NIH Grant to Develop Tuberculosis Diagnostic Device (pdf)

For further information, please contact:

Sequella, Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850
Telephone: 301-762-7776